奥兰基塞普与安慰剂诱导治疗对活动性溃疡性结肠炎患者临床应答的影响:一项随机临床试验
这项随机、双盲、安慰剂对照2期试验在东亚22个中心纳入91例活动性溃疡性结肠炎成人患者,按1:1:1随机接受奥兰基塞普600 mg、300 mg或安慰剂每两周静脉输注12周。第12周时,600 mg组临床应答率高于安慰剂组,调整差异为26.6%(90% CI,6.2%至47.1%;P=0.03),300 mg组与安慰剂组无显著差异;600 mg组25项次要结局中16项有统计学意义,300 mg组6项有统计学意义。
要点
- 奥兰基塞普600 mg组第12周临床应答率为58.6%(17/29),安慰剂组为34.5%(10/29),调整差异26.6%(90% CI,6.2%至47.1%;P=0.03)。
- 奥兰基塞普300 mg组临床应答率为43.3%(13/30),与安慰剂组调整差异8.3%(90% CI,-12.6%至29.1%;P=0.52),未达统计学显著。
- 治疗相关不良事件发生率:600 mg组53.3%(16/30),300 mg组58.1%(18/31),安慰剂组50%(15/30)。
核心结论
- 在活动性溃疡性结肠炎患者中,每两周静脉输注奥兰基塞普600 mg(而非300 mg)第12周临床应答可能性高于安慰剂。
- 需要进一步研究以重复验证并评估长期疗效和安全性。
研究设计与样本
- 随机、双盲、安慰剂对照2期试验,在东亚22个临床研究中心开展。
- 纳入91例活动性溃疡性结肠炎成人患者(全Mayo评分≥5、直肠出血评分≥1、内镜评分≥2),且对常规治疗应答不足。
- 患者按1:1:1随机接受每两周静脉输注奥兰基塞普600 mg(n=30)、300 mg(n=31)或安慰剂(n=30),持续12周。
- 2018年2月开始招募患者,最终随访于2020年12月完成;79例(86.8%)完成试验。
主要发现
- 第12周临床应答:奥兰基塞普600 mg组17/29(58.6%),300 mg组13/30(43.3%),安慰剂组10/29(34.5%)。
- 600 mg组与安慰剂组调整差异为26.6%(90% CI,6.2%至47.1%;P=0.03);300 mg组与安慰剂组调整差异为8.3%(90% CI,-12.6%至29.1%;P=0.52)。
- 600 mg组25项次要结局中16项与安慰剂相比有统计学意义;300 mg组25项中6项有统计学意义。
- 治疗相关不良事件:600 mg组53.3%(16/30),300 mg组58.1%(18/31),安慰剂组50%(15/30)。
- 最常见的药物相关不良事件为尿胆红素、高尿酸血症和天冬氨酸氨基转移酶升高,在奥兰基塞普组均比安慰剂组更常见。
关键数值与推荐
- 主要终点为第12周临床应答,定义为总Mayo评分较基线下降≥3分且≥30%,同时直肠出血评分下降≥1分且≤1分。
- 总Mayo评分范围0-12(最差),直肠出血评分范围0-3(最差)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以重复验证并评估长期疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Olamkicept, a soluble gp130-Fc-fusion-protein, selectively inhibits interleukin 6 (IL-6) trans-signaling by binding the soluble IL-6 receptor/IL-6 complex. It has anti-inflammatory activities in inflammatory murine models without immune suppression. OBJECTIVE: To assess the effect of olamkicept as induction therapy in patients with active ulcerative colitis. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled phase 2 trial of olamkicept in 91 adults with active ulcerative colitis (full Mayo score ≥5, rectal bleeding score ≥1, endoscopy score ≥2) and an inadequate response to conventional therapy. The study was conducted at 22 clinical study sites in East Asia. Patients were recruited beginning in February 2018. Final follow-up occurred in December 2020. INTERVENTIONS: Eligible patients were randomized 1:1:1 to receive a biweekly intravenous infusion of olamkicept 600 mg (n = 30) or 300 mg (n = 31) or placebo (n = 30) for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was clinical response at week 12 (defined as ≥3 and ≥30% decrease from baseline total Mayo score; range, 0-12 [worst] with ≥1 decrease and ≤1 in rectal bleeding [range, 0-3 {worst}]). There were 25 secondary efficacy outcomes, including clinical remission and mucosal healing at week 12. RESULTS: Ninety-one patients (mean age, 41 years; 25 women [27.5%]) were randomized; 79 (86.8%) completed the trial. At week 12, more patients receiving olamkicept 600 mg (17/29 [58.6%]) or 300 mg (13/30 [43.3%]) achieved clinical response than placebo (10/29 [34.5%]), with adjusted difference vs placebo of 26.6% (90% CI, 6.2% to 47.1%; P = .03) for 600 mg and 8.3% (90% CI, -12.6% to 29.1%; P = .52) for 300 mg. Among patients randomized to receive 600 mg olamkicept, 16 of 25 secondary outcomes were statistically significant compared with placebo. Among patients randomized to receive 300 mg, 6 of 25 secondary outcomes were statistically significant compared with placebo. Treatment-related adverse events occurred in 53.3% (16/30) of patients receiving 600 mg olamkicept, 58.1% (18/31) receiving 300 mg olamkicept, and 50% (15/30) receiving placebo. The most common drug-related adverse events were bilirubin presence in the urine, hyperuricemia, and increased aspartate aminotransferase levels, and all were more common in the olamkicept groups compared with placebo. CONCLUSIONS AND RELEVANCE: Among patients with active ulcerative colitis, biweekly infusion of olamkicept 600 mg, but not 300 mg, resulted in a greater likelihood of clinical response at 12 weeks compared with placebo. Further research is needed for replication and to assess longer-term efficacy and safety. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03235752.
引用
- Zhang S, Chen B, Wang B, et al. Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis: A Randomized Clinical Trial. JAMA. 2023. PMID: 36881032. doi:10.1001/jama.2023.1084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。